[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
October 7, 1961

Propionyl Erythromycin Ester Lauryl Sulfate and Jaundice

Author Affiliations

Executive Director of Medical Research Eli Lilly and Company, Indianapolis 6

JAMA. 1961;178(1):89-90. doi:10.1001/jama.1961.03040400091023

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  In the past 6 months we have received clinical and laboratory data from physicians, indicating that on rare occasions a patient receiving propionyl erythromycin ester lauryl sulfate (Ilosone) may develop sensitivity to the drug manifested by reversible jaundice and liver function test changes of the intrahepatic cholestasis type. Laboratory studies in 7 well-studied patients have been characterized by increased direct-reacting bilirubin levels, negative or weakly positive cephalin flocculation and thymol turbidity tests, elevated serum glutamic oxalacetic transaminase levels (in the range of 100 to 300 units), peripheral eosinophilia, normal cholecystograms, and in some instances elevated alkaline phosphatase levels.In 4 of these 7 patients, symptoms of abdominal distress and jaundice recurred on administration of a second course of the antibiotic, and in one, the symptoms reappeared on readministration of a third course of therapy. A fifth patient developed jaundice following a course of therapy, and then received

First Page Preview View Large
First page PDF preview
First page PDF preview